Godspower Akpomiemie to Humans
This is a "connection" page, showing publications Godspower Akpomiemie has written about Humans.
Connection Strength
0,306
-
Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa. J Int AIDS Soc. 2024 Jul; 27(7):e26268.
Score: 0,018
-
Determinants of early change in serum creatinine after initiation of dolutegravir-based antiretroviral therapy in South Africa. Br J Clin Pharmacol. 2024 May; 90(5):1247-1257.
Score: 0,018
-
Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG. Clin Infect Dis. 2023 04 17; 76(8):1492-1495.
Score: 0,017
-
Slow and Steady But Not Related to HIV Stigma: Physical Activity in South Africans Living with HIV and Chronic Pain. AIDS Behav. 2023 Jun; 27(6):1950-1961.
Score: 0,016
-
Pharmacokinetic and pharmacogenetic associations with dolutegravir neuropsychiatric adverse events in an African population. J Antimicrob Chemother. 2022 10 28; 77(11):3110-3117.
Score: 0,016
-
Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection. J Antimicrob Chemother. 2022 09 30; 77(10):2706-2712.
Score: 0,016
-
Quality of life and associated factors among people receiving second-line anti-retroviral therapy in Johannesburg, South Africa. BMC Infect Dis. 2022 May 12; 22(1):456.
Score: 0,016
-
Concentration-response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy. Br J Clin Pharmacol. 2022 03; 88(3):883-893.
Score: 0,015
-
Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial. AIDS. 2021 12 15; 35(Suppl 2):S173-S182.
Score: 0,015
-
CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz. Clin Infect Dis. 2021 12 06; 73(11):e3902-e3909.
Score: 0,015
-
Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa. AIDS. 2021 02 02; 35(2):205-211.
Score: 0,014
-
Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase. Nat Commun. 2020 12 01; 11(1):5922.
Score: 0,014
-
High individual pain variability in people living with HIV: A graphical analysis. Eur J Pain. 2021 01; 25(1):160-170.
Score: 0,014
-
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020 10; 7(10):e666-e676.
Score: 0,014
-
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. N Engl J Med. 2019 08 29; 381(9):803-815.
Score: 0,013
-
Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial. Lancet HIV. 2019 07; 6(7):e428-e437.
Score: 0,013
-
Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial. J Acquir Immune Defic Syndr. 2019 02 01; 80(2):224-233.
Score: 0,012
-
CD4 cell count variability with repeat testing in South Africa: Should reporting include both absolute counts and ranges of plausible values? Int J STD AIDS. 2018 11; 29(11):1048-1056.
Score: 0,012
-
Is laboratory screening prior to antiretroviral treatment useful in Johannesburg, South Africa? Baseline findings of a clinical trial. BMC Public Health. 2017 Jul 04; 17(Suppl 3):445.
Score: 0,011
-
Clinical and virologic response to episodic acyclovir for genital ulcers among HIV-1 seronegative, herpes simplex virus type 2 seropositive African women: a randomized, placebo-controlled trial. Sex Transm Dis. 2012 Jan; 39(1):21-4.
Score: 0,008
-
Pregnancy, contraceptive use, and HIV acquisition in HPTN 039: relevance for HIV prevention trials among African women. J Acquir Immune Defic Syndr. 2010 Apr; 53(5):606-13.
Score: 0,007
-
Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS. 2009 Feb 20; 23(4):461-9.
Score: 0,006
-
Comparison of cervicovaginal lavage, cervicovaginal lavage enriched with cervical swab, and vaginal tampon for the detection of HIV-1 RNA and HSV-2 DNA in genital secretions. J Acquir Immune Defic Syndr. 2008 Dec 01; 49(4):406-9.
Score: 0,006